ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study
Objective: To investigate the efficacy and safety of ADS-5102 (amantadine HCl) extended release capsules 340 mg daily at bedtime for the treatment of levodopa-induced dyskinesia…Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease
Objective: To examine the long-term effect of repeated boosts of intravenous amantadine in patients with PD with and without response fluctuations and dyskinesias. Background: Amantadine…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia
Objective: Aim of this study was to identify the degree of cognitive dysfunction in patients with subcortical Parkinsonian dementia, during the neuroprotective therapy. Background: Parkinson's…Parkinson’s syndrome as possible manifestation of lamina quadrigemina tumor or inflammation
Objective: Objective of this report is to discuss the case of Parkinson's syndrome (PS) in 22 y.o. patient on the background of the pathological process…